Antibodies to EGF Receptor Family Members Can Upregulate Tumor Immunity

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Immunologic mechanisms critically impact cancer therapy response.
• Monoclonal antibodies (mAbs) targeting epidermal growth factor receptor (EGFR) are clinically approved.
• Existing therapies like lung cancer vaccines targeting epidermal growth factor (EGF) show some clinical benefits.

Purpose of the Study:

• To investigate if mAbs against EGFR, EGF, and tumor growth factor alpha (TGF-α) can enhance tumor-destructive immune responses.
• To evaluate the efficacy of these mAbs in facilitating a tumor-specific immunologic attack.

Main Methods:

• In vitro studies using mouse tumor models (SW1 melanoma, B16 melanoma, ID8 ovarian carcinoma) to assess Th1 response generation and tumor cell killing by spleen cells upon mAb treatment.
• Pilot experiments involving intraperitoneal injection of mAbs (anti-TGF-α, anti-PD-1, or combination) into mice with established SW1 melanoma.

Main Results:

• All three tested mAbs (anti-EGFR, anti-EGF, anti-TGF-α) stimulated an in vitro Th1 response and tumor cell killing.
• The mAb targeting TGF-α demonstrated the highest efficacy.
• Tumor lines releasing TGF-α were more susceptible to treatment.
• A combination of anti-TGF-α and anti-PD-1 mAbs achieved complete tumor eradication in mice with established SW1 melanoma, whereas single-agent therapies did not.

Conclusions:

• Monoclonal antibodies targeting TGF-α can stimulate tumor-destructive immune responses.
• Combination therapy with anti-TGF-α and anti-PD-1 mAbs offers a potential curative strategy for established tumors.
• Targeting TGF-α in conjunction with immune checkpoint inhibitors like PD-1 warrants further investigation for cancer treatment.